Alnylam Pharmaceuticals is a leader in RNAi therapeutics developing breakthrough treatments for rare genetic diseases with a recently achieved profitable fiscal year 2025.
Investors may favor Alnylam due to its recent transition to profitability and the potential for significant revenue growth as new therapies enter commercialization phases. The company's diverse pipeline targeting multiple organ systems beyond the liver offers a clear pathway to expand its addressable market and mitigate dependence on single-indication sales. Strong cash reserves of $1.66B provide ample liquidity to fund ongoing research without immediate need for dilutive capital raising.
Skeptics might cite the company's historically large retained earnings deficit of -$6.70B as an indicator of past financial instability that could persist if new drugs fail to gain approval. High operating expenses and substantial R&D spending create vulnerability to market headwinds or pricing pressure from competitors entering the RNAi space. Dependence on licensing revenue streams introduces uncertainty regarding partner performance and the eventual impact of expiring patent protections on future earnings.
Alnylam Pharmaceuticals is a pioneering biopharmaceutical company focused on developing RNA interference (RNAi) therapeutics to treat rare genetic diseases and select common conditions. The company operates primarily in the United States and international markets, commercializing its proprietary drug portfolio through direct sales and strategic collaborations. Key products include Onpattro, Givlaari, and Amvuttra, targeting liver-related disorders such as hereditary transthyretin amyloidosis (hATTR) and hypercholesterolemia.
Fiscal year 2025 marked a significant turnaround with net profit reaching $313.7M against revenue of $3.71B, reflecting improved operational efficiency and robust demand for existing therapies. While operating expenses remain elevated at $2.54B due to R&D investments totaling $1.32B, the shift from losses in prior years demonstrates a maturing business model capable of generating substantial cash flow from operations of $524.1M.
The biotechnology sector is characterized by high failure rates but offers immense reward potential for companies with proprietary platforms that can bring first-in-class therapies to market. Regulatory scrutiny remains intense for gene-silencing technologies, requiring extensive clinical data to demonstrate safety and efficacy before gaining approval from agencies like the FDA and EMA. Market consolidation is common as smaller biotechs partner with large pharma firms to leverage their distribution networks and marketing expertise.
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue | $1.04B | $1.83B | $2.25B | $3.71B |
| Cost of Revenue | $140.2M | $268.2M | $306.5M | $677.2M |
| Gross Profit | $897.2M | $1.56B | $1.94B | $3.04B |
| Operating Expenses | $1.68B | $1.84B | $2.12B | $2.54B |
| Operating Income | $-785.1M | $-282.2M | $-176.9M | $501.6M |
| R&D | $883.0M | $1.00B | $1.13B | $1.32B |
| G&A | $770.7M | $795.6M | $975.5M | $1.21B |
| Stock-Based Comp | $230.6M | $221.7M | $272.1M | $348.2M |
| Depreciation | $39.1M | $51.6M | $55.1M | $54.8M |
| Other OpEx | $28.6M | $42.2M | $16.9M | $4.7M |
| Non-Operating Income | $-341.9M | $-151.3M | $-200.5M | $-178.4M |
| Interest Expense | $156.0M | $121.2M | — | — |
| Interest Income | — | $95.6M | $122.0M | $111.5M |
| Pre-Tax Income | $-1.13B | $-433.5M | $-377.4M | $323.2M |
| Income Tax | $4.2M | $6.7M | $-99.2M | $9.4M |
| Continuing Ops | $-1.13B | $-440.2M | $-278.2M | $313.7M |
| Discontinued Ops | $0 | $0 | $0 | $0 |
| Net Income | $-1.13B | $-440.2M | $-278.2M | $313.7M |
| Minority Interest | $0 | $0 | $0 | $0 |
| Net to Common | $-1.13B | $-440.2M | $-278.2M | $313.7M |
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Current Assets | $2.69B | $2.98B | $3.30B | $4.05B |
| Cash & Equivalents | $866.4M | $812.7M | $966.4M | $1.66B |
| Accounts Receivable | $238.0M | $327.8M | $405.3M | $777.6M |
| Inventory | $129.0M | $89.1M | $78.5M | $82.7M |
| Prepaid Expenses | $132.9M | $126.4M | $117.0M | $281.9M |
| Other Current Assets | $1.33B | $1.63B | $1.73B | $1.25B |
| Long-Term Assets | $854.1M | $847.2M | $944.7M | $915.7M |
| PP&E (Net) | $523.5M | $526.1M | $502.8M | $513.1M |
| Operating Leases | $215.1M | $199.7M | $191.1M | $194.9M |
| Other LT Assets | $115.5M | $121.4M | $250.8M | $207.6M |
| Total Assets | $3.55B | $3.83B | $4.24B | $4.97B |
| Current Liabilities | $767.9M | $967.8M | $1.19B | $1.47B |
| Accounts Payable | $98.1M | $55.5M | $88.4M | $115.7M |
| Current Leases | $42.0M | $41.5M | $41.9M | $45.5M |
| Deferred Revenue | $42.1M | $102.8M | $55.5M | $4.8M |
| Other Current Liab | $40.3M | $55.0M | $113.0M | $220.1M |
| Long-Term Liabilities | $2.94B | $3.08B | $2.99B | $2.71B |
| LT Operating Leases | $261.3M | $243.1M | $229.5M | $225.1M |
| Other LT Liab | $2.48B | $2.65B | $2.76B | $2.49B |
| Total Liabilities | $3.70B | $4.05B | $4.17B | $4.18B |
| Shareholders' Equity | $-158.2M | $-220.6M | $67.1M | $789.2M |
| Retained Earnings | $-6.57B | $-7.01B | $-7.29B | $-6.70B |
| AOCI | $-44.7M | $-23.4M | $-34.5M | $-20.1M |
| Total L&E | $3.55B | $3.83B | $4.24B | $4.97B |
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Net Income (CFO) | $-1.13B | $-440.2M | $-278.2M | $313.7M |
| Non-Cash Adjustments | $345.8M | $376.4M | $344.5M | $-283.3M |
| Working Capital Changes | $244.1M | $168.0M | $-74.6M | $493.6M |
| Cash from Operations | $-541.3M | $104.2M | $-8.3M | $524.1M |
| Capital Expenditures | $72.1M | $62.2M | $34.3M | $58.7M |
| Cash from Investing | $169.4M | $-336.4M | $-116.8M | $436.3M |
| Cash from Financing | $425.8M | $172.1M | $294.2M | $-305.2M |
| FX Effect | $-7.4M | $6.4M | $-15.2M | $34.9M |
| Net Change in Cash | $46.4M | $-53.7M | $153.8M | $690.2M |
| Beginning Cash | $822.2M | $868.6M | $814.9M | $968.7M |
| Ending Cash | $868.6M | $814.9M | $968.7M | $1.66B |
The company's revenue streams are driven by its commercialization of RNAi drugs targeting specific protein expression, including products for hATTR like Onpattro and Amvuttra, PCSK9 inhibitors like Givlaari for hypercholesterolemia, and emerging therapies in metabolic disorders. Revenue growth is supported by expanding patient access programs, international market expansion, and royalty payments from strategic licensing partnerships with major pharmaceutical firms.
Potential risks include limited commercialization of non-liver delivery platforms which could restrict future revenue diversification beyond current approved therapies. The company faces ongoing patent expiration challenges that may impact royalty income and necessitate costly new product launches to maintain growth momentum. Clinical trial failures or regulatory setbacks for pipeline candidates could significantly delay product approvals and erode investor confidence in the company's innovation capabilities.
Alnylam possesses a robust proprietary RNAi platform that enables precise gene silencing, creating high barriers to entry for competitors. The company benefits from strong intellectual property protection across its portfolio and an established clinical development track record that has successfully navigated regulatory approvals in the US and Europe. Strategic partnerships with large pharmaceutical companies provide essential commercial scale and shared risk for expensive drug development programs.
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.